Peringkat dalam Saham
#2339
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Kapitalisasi Pasar
$8.97B
Perubahan (1 tahun)
192.01%
Perdagangan Immunovant, Inc. (IMVT)
Harga IMVT dengan kapitalisasi pasar B
Kapitalisasi pasar dari Immunovant, Inc.(IMVT)
Kapitalisasi Pasar: $8.97B
Per August 2026, Immunovant, Inc. memiliki kapitalisasi pasar sebesar $8.97B. Ini menjadikan Immunovant, Inc. sebagai perusahaan 2339th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Immunovant, Inc. dari 2019 hingga 2026
IMVT dibandingkan dengan 5 teratas stocks paling populer
| Harga IMVT |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.118T
|
+56,928.00%
|
|
|
|
|
$4.545T
|
+50,544.31%
|
|
|
|
|
$4.162T
|
+46,272.60%
|
|
|
|
|
$3.634T
|
+40,390.13%
|
|
|
|
|
$2.805T
|
+31,156.55%
|
